News

Bristol Myers Squibb Acquires RayzeBio in a Strategic Move to Expand Radiopharmaceutical Capabilities

In a significant development in the pharmaceutical industry, Bristol Myers Squibb (BMS) has announced the acquisition of RayzeBio, a company …

Continue ›››

C4 Therapeutics and Merck Collaborate on Innovative Cancer Treatment

In a recent move in the biotechnology sector, C4 Therapeutics, Inc. (C4T) has announced a collaboration with pharmaceutical giant Merck …

Continue ›››

LegoChem Biosciences Strikes Licensing Deal with Janssen for ADC Development

In a new development in the field of cancer treatment, LegoChem Biosciences, Inc., a South Korean biopharmaceutical firm, has announced …

Continue ›››

Unnatural Products Secures $32M to Advance Drug Development with AI-Enhanced Macrocycles

Santa Cruz-based biotech company, Unnatural Products, Inc. (UNP), has recently secured a significant investment of $32 million in its Series …

Continue ›››

SiSaf Advances in Alopecia Treatment with Phase II Trial of Bio-Courier® Technology

In a new development in the field of dermatological therapeutics, SiSaf Ltd, a biopharmaceutical company based in Guildford, UK, has …

Continue ›››

Vandria Gains Momentum with $20.6M Funding to Propel Novel CNS and Mitochondrial Therapies

Vandria SA, a Swiss biotechnology firm specializing in mitochondrial therapeutics, recently announced a significant milestone in its journey. The company …

Continue ›››

ACSR Partners with Proscia to Accelerate Global HIV Cancer Research Through Advanced Digital Pathology Platform

In a recent development for the scientific community, the AIDS and Cancer Specimen Resource (ACSR) has enhanced its ability to …

Continue ›››

Mitsubishi VC Arm Leads $7.5M Financing for PharmEnable's AI in Drug Discovery Efforts

PharmEnable, an innovative drug discovery firm, recently secured $7.5M in Pre-Series A financing, reflecting growing confidence in its proprietary AI-based …

Continue ›››

British Patient Capital Backs Notable Cancer Research with $7 million Investment in Grey Wolf Therapeutics

British Patient Capital, a subsidiary of the British Business Bank, invested $7 million in Grey Wolf Therapeutics, an Oxford-based biotech …

Continue ›››

Endogena Therapeutics Doses First Patient With Novel Treatment For All Retinitis Pigmentosa Types

Endogena Therapeutics, a biotech company that focuses on the first-in-class endogenous regenerative medicines, just announced treating the first patient with …

Continue ›››

Emerging AI Player in the Drug Discovery Race Promises to Screen Ultra-large Chemical Spaces Within Hours

Receptor.AI, a UK-based start-up company which integrates artificial intelligence (AI) into drug discovery, just announced the public launch of the …

Continue ›››

AI Hunt for ALS Treatment Continues With 28 Novel Targets Revealed by Insilico Medicine

Insilico Medicine identified 28 new targets for the treatment of amyotrophic lateral sclerosis (ALS) using its proprietary AI-driven platform PandaOmics. …

Continue ›››